Public Archives - Green Market Report

Debra BorchardtDebra BorchardtMarch 23, 2021
Trulieve3.jpg?fit=960%2C720&ssl=1

5min10400

Trulieve Cannabis Corp. (OTCQX: TCNNF) announced revenue grew 111% to $168.4 million for the fourth quarter ending December 2020 versus last year’s revenue of $79.7 million for the same time period. This beat the average analyst estimate for $162 million according to Yahoo Finance. Trulieve‘s net income fell 75% to $3 million for the quarter versus $12.2 million for the same time period in 2019. 

For the full year, Trulieve delivered revenue of $521.5 million, representing year-over-year growth of 106%. For the full year, the company reported a net income of $63.0 million resulting in full-year earnings per share of $0.53 on a fully diluted basis. Absent the revaluation of our debt warrants, an impact of $42.7 million for the year, adjusted net income would have been $105.7 million resulting in earnings per share of $0.89 on a fully diluted basis, which beat estimates by $0.38.

“2020 was a year of foundational growth that sets the stage for what we expect will be an exciting and transformational year of national expansion. We had an excellent fourth quarter with strong financial performance capping off our highest annual revenue, net income and Adjusted EBITDA year to date. Our results reflect the outstanding work we’ve accomplished as a company and our focus on continuous improvement. Our full-year Adjusted EBITDA in 2020 was nearly equal to our prior year revenue,” stated Kim Rivers, Trulieve CEO.

Trulieve also reported that its 2020 Adjusted EBITDA of $251.0 million, was a year-over-year growth of 99%. The adjusted EBITDA of $78.2 million in the fourth quarter was an increase of 19% from the third quarter. The company delivered $99.6 million in cash flows from operations for the year.

Outlook

Based on Trulieve’s markets, current regulations, and foreseeable store growth, the company estimates 2021 revenues in the range of $815 million to $850 million, and $355 million to $375 million in adjusted EBITDA. Guidance for 2021 incorporates a full year of operations from Trulieve’s  Pennsylvania operations, continued growth in Florida as well as the Company’s Massachusetts, Connecticut, and California locations.

Operational Highlights

The company listed the following operational achievements in a statement:

  • Approved to start growing plants at our Tier 9 facility in Holyoke by the Cannabis Control Commission in Massachusetts.
  • Expanded national footprint in the Northeast with closings of the acquisition of Solevo Wellness, adding three operational dispensaries in Pennsylvania, and PurePenn, a cultivator and processor supplying wholesale product to 100% of dispensary operations in the state.
  • Entered a 6 th state with the award of a processor permit by the West Virginia Office of Medical Cannabis and four dispensary permits subsequent to year-end. Announced a Definitive Agreement for the acquisition of Mountaineer Holding, LLC, a West Virginia company that holds a cultivation permit and two dispensary permits, resulting in a vertical platform.
  • Opened 11 new retail dispensaries in the fourth quarter, ending the year with 75 stores in the U.S. Added over 200,000 square feet of cultivation facilities during 2020, ending the year with almost 2 million square feet of cultivation facilities, to support this explosive growth of new stores.
  • Ended 2020 with a 49% market share in oil and 53% market share in flower in the state of Florida and achieved record flower and oil sales at the end of December, selling 93.7M mgs of oil and 36,330 ounces, or over one ton of flower.

StaffStaffDecember 17, 2020
0-5-scaled.jpeg?fit=1200%2C365&ssl=1

3min5420

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a leader in cannabis research and the development of clinically validated cannabis medicines, just announced its newest licensing agreement for its HOPE™ line of products, Zelira’s top-selling treatment developed for autism patients. Under the agreement with Alternative Solutions, a licensed grower, manufacturer and distributor of medical cannabis products in the District of Columbia (Washington DC), HOPE™ will be produced and distributed throughout the legal DC medical cannabis market beginning in Q2 2021.

“We are thrilled to have Alternative Solutions as a partner to launch HOPE™ in the nation’s capital,” says Dr. Oludare Odumosu, CEO & Managing Director USA for Zelira. “They are a leader in the DC medical cannabis market, and this partnership will allow legal access of HOPE™ to more patients across the country than ever before.”

Odumosu notes that this agreement with Alternative Solutions signifies HOPE’s largest expansion to date; because Washington DC has reciprocity with 32 other states in the US with approved medical cannabis programs, patients registered in those states are able to legally purchase medical cannabis products at an approved dispensary in Washington DC.

HOPE™ was formulated by Zelira Therapeutics and is the brainchild of Erica Daniels, founder of Hope Grows for Autism, a nonprofit aimed at improving the lives of families affected by autism through research, education and advocacy of medical marijuana. HOPE™ is currently available in the United States in Pennsylvania, through an exclusive license agreement with Ilera Healthcare, and in Louisiana, through an agreement with Advanced Biomedics LLC.


StaffStaffDecember 2, 2020
shutterstock_1431673145-scaled.jpg?fit=1200%2C800&ssl=1

4min6480

SprinJene and its partner Zelira Therapeutics (ASX: ZLD, OTCQB: ZLDAF) today officially launch their new CBD oral care line. In September, we reported on their partnership announcement and the future launch of their new hemp-derived CBD oral care line. The companies said their product would be available by Q4 of 2020. In a press release the companies announced the first product from its line will be available on Monday, December 7th at SprinJene.com.

This new launch already expands upon SprinJene’s premium natural oral care products which are Gluten-Free, Cruelty-Free, Vegan, Kosher, USDA Bio-preferred, and Halal oral care. The New Jersey based company which recently received its first ADA (American Dental Association) seal of acceptance for its Fresh Boost toothpaste. The formula for SprinJene products holds a patented formula of zinc and black seed oil, which together can provide relief from dry mouth, control tartar growth, and deliver long-lasting oral freshness. Black Seed oil and zinc have been shown to fight gingivitis (gum disease) and reduce gum inflammation. Their products are nationwide and can be found in such retails as Costco, Bed Bath & Beyond, and VitaCost and online at Walmart.com and Amazon.

Dr. Sayed Ibrahim, CEO of SprinJene said, “Our brand is built on harnessing the power of natural ingredients to protect and improve our oral health, and CBD, with its inherent anti-inflammatory, antibacterial and homeostatic properties are shown to be powerful tools in that fight.”

In its release, the company said research shows that incorporating CBD into oral/dental care results in health benefits such as: naturally eliminating decay-causing bacteria, reducing gum inflammation, restoring pH balance and increasing remineralization, reducing bone loss associated with gum disease, and helping to improve overall health.

SprinJene’s formulation was created with Zelira and uses hemp-derived broad-spectrum, THC-free CBD, unlike other brands that use hemp seed oil with no CBD. With their unique formulation which includes black seed oil as well, consumers will receive the benefits of CBD with no psychoactive “feeling of high” effects.

“We are thrilled to enter the national oral care market alongside our remarkable partner. SprinJene shares our values of aligning nature and science,” said Dr. Oludare Odumosu, Zelira’s CEO & Managing Director (USA).  “As you can see SprinJene continues to innovate and with this expansion, consumers will receive the benefits of the effectiveness of CBD and other cannabinoids improving our health from head-to-toe.”

 


StaffStaffOctober 30, 2020
shutterstock_1012237351-scaled.jpg?fit=1200%2C800&ssl=1

3min7680

Zelira Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF) just announced that its proprietary cannabinoid medicines, HOPE 1 and HOPE 2are now available by prescription to patients in Australia. The HOPE™ forumations, developed by Zelira and noted autism advocate Erica Daniels, first launched in 2019 in Pennsylvania and this fall in Louisiana. 

“We have had great success with HOPE™ in the US and are thrilled to be able to offer it to patients as a treatment option through the Therapeutic Goods Administration’s (TGA) Special Access Scheme,” says Osagie Imosogie, Chairman of Zelira Therapuetics. “Zelira is proud of this latest achievement in our mission to bring cannabinoid medicine to patients around the world.”

The HOPE cannabinoid medicines were developed to support the needs of patients with Autism Spectrum Disorder (ASD) by Daniels and Zelira Therapeutics, which then licensed the proprietary formulas to Ilera Healthcare in Pennsylvania and Ilera Holistic Healthcare in Louisiana. HOPE has since established itself as one of the top selling formulated medicinal cannabis products in Ilera Healthcare’s portfolio. 

“Autism families are finally beginning to have access to a truly better alternative than the harsh pharmaceuticals of the past and I am so proud that HOPE is now available in Australia,” says Erica Daniels, founder of Hope Grows for Autism and co-creator of the HOPE forumalations. “What started off as a labor of love to find a way to treat my own son is now helping parents around the world.” 

HOPE is part of Zelira’s family of revenue generating medicinal cannabis formulations. The products consist of two pharmaceutical-grade proprietary formulations developed as pharmaceutical-grade products targeting Autism Spectrum Disorder (ASD) as a disease indication. 

“Following the success of the HOPE™ launches in Pennsylvania and Louisiana, we are excited to make these products available to patients and physicians in Australia,” says Dr. Richard Hopkins, Zelira’s global Managing Director. “This represents another key milestone in our commitment to bring the benefits of HOPE to patients in global markets.”


StaffStaffOctober 19, 2020
shutterstock_431001775-scaled.jpg?fit=1200%2C797&ssl=1

3min10600

Mydecine Innovations Group, Inc, (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) announced the appointment of UK-based Boustead Capital Markets LLP (“Boustead”) to commence the dual listing process on the London Stock Exchange (“LSE” or the “Exchange”) for the admission of the Company’s common shares to the Standard Segment of the Official List’s Main Market.

Among the factors considered by the Company in pursuing the dual listing, Mydecine™ noted that the LSE currently has a limited number of sizable psychedelics-focused biotech companies. Mydecine, as a contributing member to Drug Science UK, the only completely independent, science-led drugs charity, believes the LSE listing will provide UK and European investors with greater, more local exposure to a new high-quality investment choice of a business type not currently available on the Exchange.

Highlights

Mydecine’s appointment of Boustead enables it to commence the LSE listing process and act on its intention for the Company’s common shares to trade on the Main Market in the next few months. In addition to its current listings in Canada, the United States, and Germany, the Company believes that a listing on the LSE makes it well-positioned to bring European investors into the Company’s share register.

The LSE listing is expected to provide all investors access and exposure to:

  • European Investor base in what the Company believes are Psychedelic-friendly countries such as the Netherlands, United Kingdom, Austria, and Portugal, to name a few
  • Support early and late-phase clinical trials
  • Expansion of the Company’s telehealth platform; Mindleap Health
  • Further development of extensive IP portfolio
  • Furthering the development of novel types of psilocybin-based medicine and unique formulations

Josh Bartch, CEO & Chairman of Mydecine Innovations Group, commented, “The Board of Directors has met a number of times deciding the best route and venue for the new listing of the Company’s securities, adding to our focus on shareholder value. We decided the LSE represented the best stock exchange for our investors, shareholders, and the ongoing growth of the Company. Additionally, it provides a great platform to measurably advance our investor reach within the European investor community. A LSE Listing offers a number of opportunities to fast-track further potential listings to exchanges such as NASDAQ or NYSE. Mydecine Innovations Group has a global reach through the Company’s various planned clinical trials, research facilities, partners and scientific advisors, some of which are located directly in the UK.”


William SumnerWilliam SumnerOctober 7, 2020
900x500.jpg?fit=900%2C500&ssl=1

6min14630

Psychedelic drugs like psilocybin are a game changer in the world of mental health sciences. There is a growing body of evidence that suggests psilocybin has the potential to help treat anxiety, depression, and post-traumatic stress disorder (PTSD). As scientific interest in psilocybin grows, so too does the attention of investors; many of whom cannot help but see the market similarities between psychedelics, pharmaceuticals, and the cannabis industries.

Indeed, the functional non-psychedelic and gourmet mushroom markets as a whole is poised for explosive growth over the next few years. By 2024 the market is expected to grow to $34.3 billion in sales according to ResearchAndMarkets.com. Recognizing the huge opportunities in these other fungi markets, dozens of companies have sprung up hoping to cash in on the psychedelic mushroom space, like Compass Pathways (NASDAQ: CMPS).

As one of the more high profile companies investigating psilocybin-based therapies, Compass has been enjoying the investor spotlight for the last several months, especially after recently announcing an upsized IPO of more than $127 million. With high profile backers like PayPal billionaire Peter Thiel, Compass has become the company du jour of the psychedelic space, but regulatory uncertainty and issues of scaling still haunt the company’s path to market.

As evidenced by the decades-long disconnect between state and federal cannabis laws, both lawmakers and regulators are slow to embrace substances that carry the social stigma of the War on Drugs, even when there is a large body of evidence suggesting therapeutic potential.

Even if Compass is able to bring a substance to market, it will be subject to heavy restrictions and a long scheduling process, which will significantly stymie any market rollout. In their IPO filing, the company admits as much.

“In addition, the scheduling process may take significantly longer than the 90-day deadline set forth in the CSA, thereby delaying the launch of our investigational COMP360 psilocybin therapy in the United States,” reads the filing.

Further, standing in the way of Compass’ dreams of market primacy is the issue of scaling. The company’s primary source of psilocybin comes from laboratory synthesis, which is prohibitively expensive. Due to the high cost of synthetic psilocybin production, Compass charges their customers anywhere between $7,000-$10,000 USD per gram, averaging out to around $13.20 per milligram.

In comparison, whole-mushroom extraction is significantly cheaper, costing around $0.76 per gram to extract psilocybin, assuming the source of the mushrooms are from a black market dealer. Now, if you can legally produce your own mushrooms, the costs only continues to decline.

Currently, the only company in the world that can legally produce pharmaceutical-grade psilocybin from whole-mushroom extraction is Mydecine Innovations Group (CSE: MYCO). Equipped with a Health Canada Schedule 1 Controlled Drugs and Substances Dealer’s Licence, Mydecine can not only produce whole-mushroom psilocybin extractions, but they can also transfer, sell, and export the substance as well. 

While Compass seems to be mired in regulatory uncertainty south of the Canadian border, Mydecine is quietly conducting, in collaboration with the Dutch Royal Army, the world’s first clinical trials into the efficacy of psilocybin in treating Post-Traumatic Stress Disorder.  Leading these efforts is a science team with a surprisingly deep bench of experts, including a seven-time Nobel Prize nominee and the former chair of the NATO research group on military mental health training.

Though Compass may have a head start, Mydecine has a much clearer path to market; due in no small part to the lack of regulatory uncertainty surrounding Mydecine’s efforts and the company’s ability to produce psilocybin at significantly lower prices. With a solid foundation moving forward, Mydecine seems poised for growth. The question is, will investors take notice?

 


StaffStaffSeptember 22, 2020
shutterstock_252335677-scaled.jpg?fit=1200%2C800&ssl=1

6min12070

The CBD market is one of the fastest growing industries in the United States. In 2017, U.S. CBD sales topped out at around $190 million. Three years later, the U.S. CBD market is a billion-dollar industry that is poised to reach $16 billion in annual sales by 2025. Enabling this rapid market expansion was the 2018 Farm Bill, which federally legalized the production, sale, and distribution of hemp and its derivatives (CBD chief among them).

Yet while the Farm Bill paved the way for this billion-dollar industry, CBD brands themselves are still struggling to access even the most basic of financial services, such as credit card payment processing. Although CBD is technically legal, it is still a substance that remains unregulated by the Food and Drug Administration.

CBD’s unregulated status creates a host of issues for brands and the ancillary companies that service them. On June 29, 2020, the U.S. Financial Crimes Enforcement Network (FinCen) issued comprehensive guidance to financial institutions working with hemp-related businesses.

Among other provisions, the memo removed the requirement that financial institutions automatically file a Suspicious Activity Report (SAR) on all hemp-related customers, making it easier for banks to service the industry.

Noticeably absent from the memo is any word regarding CBD-related businesses, due in large part to the substance’s unregulated status. Consequently, mainstream payment processors have been reluctant to embrace the CBD industry.

The only companies thus far that have been willing to service the industry are those offering high-risk merchant accounts.

A high-risk merchant account is essentially a processing account for businesses that banks would consider “high-risk.” Typically, the types of companies that open these accounts are from industries such as adult entertainment, gambling, alcohol, etc.

While a typical merchant account will charge companies around 1%-2% per transaction, high-risk merchant accounts will often charge between 3%-9% per transaction. Most notably, the payment processor Square charges CBD brands 3.9% plus $0.10 per transaction for in-person transactions, and 4.2% plus $0.30 per transaction for online purchases.

Such steep fees can make it difficult for CBD brands to prosper, especially when it comes to those that depend on online sales.

A recent report by Brightfield Group found that approximately 45% of consumers are purchasing CBD solely from the internet due to concerns from the COVID-19 outbreak. Unsurprisingly, online CBD purchasing increased by 61% from Q1 to Q2 of 2020.

The banking issue is a particularly frustrating problem for the CBD industry because, unlike the cannabis industry, CBD is legal at the federal level. For many in the industry, the assumption was that once the Farm Bill legalized hemp and CBD, that it would become easier to conduct business, but little has changed.

Recognizing the frustrations felt by those in the CBD industry, cannabis-focused compliance companies like Akerna (Nasdaq: KERN) have started to build out their platforms to support CBD brands as well. Akerna is a Denver-based compliance technology company best known for their seed-to-sale software MJ Platform.

Most recently, the company announced that they signed an agreement with Priority Technology Holdings, Inc. (Nasdaq: PRTH), to provide the hemp-CBD industry with payment processing solutions. Offering ACH, card-not-present, recurring payments, and automatic credit card information updates; Akerna aims to offer a seamless all-in-one service to both current and future CBD clients.

Looking forward, the company also hopes to leverage this agreement to help position the company as a national payment processor for the cannabis industry as well.

“With this solution, we are making it easier for our CBD and hemp clients to process payments,” said Akerna CEO, Jessica Billingsley, in a statement. “We are also well positioned to activate payment solutions through Priority for traditional cannabis sales pending legislative action at the federal level.”

Given the limited number of payment processing solutions, much less those designed specifically for the CBD industry, Akerna currently enjoys the first-mover advantage. Inevitably competitors will arise, but for now it is lonely, and profitable, at the top.

 


StaffStaffSeptember 15, 2020
cannadips-pouches-344600_1024x1024.jpg?fit=960%2C960&ssl=1

4min11310

Boldt Runners Corp., the exclusive licensee of Cannadips CBD, the Original Smokeless Dip Pouch with CBD, announced today several personnel changes, including the appointment of former tobacco executive Maura Scott as Chief Sales Officer and Chief Compliance Officer.

With over two decades of experience as a business leader, in-house and outside corporate counsel, Scott brings expertise in sales and marketing strategy development, world-class execution, and deep understanding of the legal and regulatory landscape.

“I am excited to be part of the Boldt Runners team,” said Scott.  “Cannadips CBD is a brand that has great potential in the marketplace for tobacco alternatives.  Since its launch in 2018, it has quickly gained transaction with adult consumers and is poised to expand rapidly as the Company ramps up production and distribution to more markets.  I look forward to helping the Boldt Runners team achieve its goal of reaching millions more consumers with this superb product.”

Most recently, Scott served as Vice President Northeast Region Sales at Altria Group, Inc. (NYSE: MO), where she led a team of 400 sales professionals across 13 states.  In 2018, she was recognized by her peers in the convenience industry with the Top Women in Convenience “Woman of the Year” Award.  Previously, Scott served as Assistant General Counsel at Altria where she led the Sales Practice Group. 

In her role as Chief Sales Officer and Chief Compliance Officer, Scott will focus on leading all aspects of the Company’s marketing, building and managing customer relationships, enhancing distribution logistics, growing the Cannadips CBD brand, and overseeing compliance.  Scott holds a B.A. from the University of Illinois and a J.D. from the University of Michigan Law School.

“Maura is an exceptional addition to the team,” said Boldt Runners Chief Executive Officer, Peter Diatelivi.  “Having worked with her for over a decade, first as in-house counsel and then as a fellow sales executive, I know her as someone who brings passion, vision, and strategic depth to the business.  Her keen intellect, judgment, and ability to form strong connections with colleagues and customers alike makes her the ideal person to trust with this role.”

Additionally, the Company also announced several personnel changes. Case Mandel will now serve as the Company’s President, and Ryan Ulanch has been appointed Vice President of Commercial Operations

An entrepreneur who has spent over 10 years in the cannabis and hemp industry, Case Mandel co-founded the Cannadips brand with childhood friend, Cliff Sammet, in 2016.  Mandel won Entrepreneur of the Year at the 2020 Hemp Business Awards and has become a leading expert in the new category emerging between traditional CPG and cannabinoids.  Mandel obtained an MBA from Humboldt State University and a B.S. from California Polytechnic State University in San Luis Obispo.  

Ryan Ulanch is an experienced CPG operator with over 10 years’ experience in market analysis, sales operations, corporate strategy, and project management. Before joining Boldt Runners, Ulanch worked in commercial operations at the largest wine and spirits distributor in the US, Southern Glazer’s Wine & Spirits.


StaffStaffSeptember 11, 2020
SprinJene-CBD-Toothpaste-Photo.jpg?fit=960%2C622&ssl=1

3min10940
Zelira Therapeutics (ASX: ZLD, OTCQB: ZLDAF) announced it has entered into a partnership agreement with New Jersey based oral care company SprinJene to launch hemp-derived CBD dental products. SprinJene says it will bring its CBD toothpaste to market by the end of Q4for  distribution across retail and other channels across the US. This will be the first CBD product for the brand. Dr. Sayed Ibrahim, CEO of SprinJene said “We are excited about the partnership with Zelira Therapeutics and look forward to the impact that our products will have in the oral care market.” The company’s current line of products are nationwide and can be found at Walmart, Costco, Bed Bath & Beyond, Amazon, and VitaCost. Ibrahim continues, “Our collaboration to commercialize the most advanced hemp-derived cannabinoid-based oral care products expands our reach into new oral care markets where every person can access the daily benefit of using our products.”
 
Dr. Oludare Odumosu, CEO and Managing Director (USA) of Zelira said, “This partnership with SprinJene will commercialize these new and advanced oral care cannabinoid-based products. Our firm remains focused on unlocking the benefits of cannabinoid-based applications as we continue to expand our company’s reach into new and lucrative markets. ”
 
Zelira is one of the global leaders in developing clinically validated cannabis medicines, this will be their first of five over-the-counter oral cannabinoid products they are on track to launch globally. will bring to market.  SprinJene® states it is a socially conscious brand dedicated to marrying the benefits of science and nature in the creation of Gluten-Free, Cruelty-Free, Vegan, Kosher, USDA Bio-preferred, and Halal oral care. The line is manufactured by New Jersey based Health and Natural Beauty USA Corp. where Zelira-SprinJene products will be manufactured. 

StaffStaffAugust 18, 2020
shutterstock_1789366847-scaled.jpg?fit=1200%2C789&ssl=1

4min21390

Under the coverage of a Health Canada Schedule 1 Controlled Drugs and Substances Dealer’s License, Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine™” or the “Company”) announced that it is the first organization to exercise its cGMP capabilities under a special license to legally produce, transfer, sell, and export pharmaceutical-grade psilocybin, naturally derived from whole-mushroom extraction.

Mydecine™ has the full range of capabilities to extract fungi’s natural psychedelic compounds, such as psilocybin and psilocin from certain species of fruiting body mushrooms all the way through to distribution. Mydecine™ also has the ability to conduct the most advanced techniques to produce purified pharmaceutical-grade extract, then legally export its finished byproducts to its various research partners throughout the world, including but not limited to the Imperial College of London and Johns Hopkins University.

The Company is also capable of supporting commercial research institutions with product donations, including charitable contributions to provide its purified extracts and formulations to end-of-life distressed patients. The announcement comes on the heels of a recent landmark decision by Health Canada to permit four terminally ill patients to consume psilocybin mushrooms to ease their distress. This historic decision establishes a precedent that will pave the way for a wider adoption of psilocybin-based therapies.

“Mydecine’s breakthrough to legally supply naturally-sourced psilocybin within our spore-to-sale™ process will be a major advancement for mental therapeutics, due to the fact that these unique psychedelic compounds are both safe and effective for afflictions, such as depression, anxiety, and PTSD,” quoted Damon Michaels, COO and Co-Founder of Mydecine™.

There is still debate as to which is more successful in psychedelic-based treatments between naturally derived psilocybin or the use of a synthetic form. Given Mydecine’s full legal ability to access both types of active compounds, the Company is poised to internally answer that question as well as aid various qualified groups also conducting this type of research. In theory, there are a plethora of added benefits in regard to the entourage effect of naturally-sourced psilocybin versus the synthetic route. Additionally, Mydecine™ is developing a number of unique API’s from their naturally-sourced cGMP psychedelic extracts. Mydecine™ will also be conducting R&D to produce novel proprietary formulations by synergizing psychedelic fungi compounds with other various API’s; Mydecine™ will then attach their formulations to their exclusive delivery mechanisms. Mydecine™ plans to utilize these psychedelic medicinal formulations in various clinical environments around the world in aspiration to better the lives of many.

The Company notes that although several international companies and research institutions are permitted to utilize synthesized psilocybin, the process is extremely challenging and cost prohibitive with a single gram having the price tag of thousands of dollars. Being able to legally extract psilocybin from its natural source, Mydecine™ will hope to reduce these significant costs and improve the scalability of world-class research initiatives and novel therapies.

CEO and Director of Mydecine™, Joshua Bartch stated, “We are extremely grateful to have the ability to provide cGMP psychedelic API’s to qualified organizations, research partners, nonprofits, and clinical groups throughout the globe. We believe the reason current psilocybin-based research initiatives come with a very high cost using inefficiently produced synthetic psilocybin is simply due to a lack of capabilities and legal restraints. Mydecine’s legal capabilities through the dealer’s license will incorporate our range of abilities, which will be valuable for naturally-sourced medicine paired with new-age technology. We believe our achievement is the first-of-its-kind.”


Get the latest news delivered straight to your inbox!

Join to receive our weekly digest of today's most critical financial news on the cannabis industry

We respect your privacy. Your information is never shared.


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 10 hours

So much happened this week in the industry. Did you miss something? Watch from…

@GreenMarketRpt – 10 hours

Welcome to the weekend! Catch up on all the of the week with #GreenMarketReport…

Back to Top